Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 6, 2014

Primary Completion Date

January 7, 2015

Study Completion Date

January 7, 2015

Conditions
Peanut Allergy
Interventions
BIOLOGICAL

AR101 powder provided in capsules

Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

BIOLOGICAL

Placebo powder provided in capsules

Study product formulated to contain only inactive ingredients for use as defined in the protocol

Trial Locations (8)

10029

Mount Sinai Medical Center, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

27599

University of North Carolina, Chapel Hill

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

72202

Arkansas Children's Hospital, Little Rock

75235

Children's Medical Center Dallas, Dallas

92123

UC San Diego, San Diego

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Aimmune Therapeutics, Inc.

INDUSTRY

NCT01987817 - Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT | Biotech Hunter | Biotech Hunter